Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

December 5, 2016

Study Completion Date

December 5, 2016

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

Recombinant human C1 esterase inhibitor

Subjects will receive escalating doses I-IV as both IV and SC injections

DRUG

Placebo

Subjects will receive matching placebo

DRUG

SHP623

DRUG

Placebo

Trial Locations (1)

Clinical Pharmacology of Miami, Miami